摘要
为探讨替尼泊甙（威猛）对脑胶质瘤术后复发的预防作用，将６０例手术切除的脑胶质瘤患者分为两组：单纯手术组３０例，手术加威猛组３０例。术后静脉途径给威猛剂量为６０ｍｇ／ｍ２，３～４天，疗程间隔４～６周，平均每人４．６个疗程。随访时间２４～３０月，中位随访期２６月。结果表明单纯手术组和手术加威猛组的复发率分别为６月３６．７％和１６．７％（Ｐ＞０．０５），１２月５３．７％和２６．７％（Ｐ＜０．０５），１８月５６．７％和３０．０％（Ｐ＜０．０５），２４月７３．３％和４６．７％（Ｐ＜０．０５）。两组病人的死亡率分别为６月３３．３％和１０％，１２月４６．７％和２０．０％，１８月５３．３％和２６．７％，２４月７０．０％和４３．３％，Ｐ值均＜０．０５。两组病人２４个月后复发病例的无复发生存期比较，差异有显著性（Ｐ＜０．０５）。提示威猛能够延长脑胶质瘤患者术后的复发时间，降低其术后的复发率和死亡率。主要不良反应为骨髓抑制。
The study included 60 patients with cerebral glioma who were operated in Tongji Hospital,Wuhan city from August,1994 to June,1996.All the patients were divided into two groups.Group one was operated alone,another was operated plus VM 26 chemotherapy,each group included 30 patients.The dose of VM 26 was 60 mg/m 2/day.All patients were followed for 24 to 30months.The recurrence rates of two group patients were 36.7%,16.7% in 6 months,53.7%,26.7% in 12 months,56.7%, 30.0% in 18 months,73.3%,46.7% in 24 months respectively.The difference was statistically significant in 12 months,18 months and 24 months ( P <0.05).The mortality rates of two groups were 33.3%,10% in 6 months,46.7%,23.3% in 12 months,53.7%,26.7% in 18 months,and 70.0%,43.4% in 24 months respectively.The difference was also statistically significant ( P <0.05).The results indicate that VM 26 can reduce the recurrence rate and mortality of glioma.The main side effects observed were marrow supression,alopecia and etc.
出处
《实用肿瘤杂志》
CAS
北大核心
1998年第5期279-280,共2页
Journal of Practical Oncology
关键词
神经胶质瘤
药物疗法
脑肿瘤
替尼泊甙
复发
glioma/drug therapy glioma/mortality teniposide/therapeutic use recurrence
